AstraZeneca has announced $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D.
This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country, powering growth and delivering next-generation medicines for patients in America and worldwide.
The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the Company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products.
The new state-of-the-art centre will produce small molecules, peptides, and oligonucleotides. This multi-billion-dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production.
Pascal Soriot CEO – AstraZeneca
“The announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”
Howard Lutnick, US Secretary of Commerce, said that, “For decades Americans have been reliant on a foreign supply of key pharmaceutical products. President Trump and our nation’s new tariff policies are focused on ending this structural weakness.”
“We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here,” Lutnick added.
